ArticleOrphanet journal of rare diseases2026
Orphan drug propranolol for infantile hemangioma: ten-year real-world safety data from the FAERS database.
Article in Orphanet journal of rare diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Pharmacovigilance assessment of gout: a real-world study using the FAERS database.Frontiers in pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivePropranolol, a non-selective β-adrenergic receptor blocker, is the first FDA-approved orphan drug for the treatment of infantile hemangioma (IH). While it has demonstrated substantial therapeutic benefits, the safety profile of propranolol in infants remains insufficiently characterized, particularly in real-world settings.
methodsA retrospective pharmacovigilance analysis of FAERS reports from Q1 2015 to Q4 2024 was conducted, applying four signal detection algorithms (ROR, PRR, BCPNN, MGPS) to identify disproportional AE signals related to propranolol in IH.
resultsA total of 1615 AE reports were included. Signal detection identified events across 20 System Organ Classes (SOCs), with vascular, psychiatric, and metabolism and nutrition disorders being most prominent. At the Preferred Term (PT) level, the most frequently reported AEs were sleep disorder (n = 149, ROR = 32.67), peripheral coldness (n = 87, ROR = 108.73), and hypoglycaemia (n = 62, ROR = 22.95), which were pharmacologically plausible and clinically relevant.
conclusionsThis study identified safety signals associated with propranolol in infants with IH, highlighting risks across organ systems. These findings support the need for vigilant monitoring, individualized risk assessment, and refinement of labeling recommendations to optimize safety in this vulnerable population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.